NFE2L2 and cancer: Importantly, persistent activation of NRF2 that is induced pharmacologically in KEAP1-NRF2-intact cancer cells also decreases NEAA synthesis and makes them rely on exogenous NEAAs (LeBoeuf et al. 2019).